News/ News/ R&D VistaGen’s horizons may shrink after clinical trial setback Phil Taylor central nervous system, Psychiatry, social anxiety disorder, VistaGen Therapeutics 0 Comment Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed Share X VistaGen’s horizons may shrink after clinical trial setback https://pharmaphorum.com/news/vistagens-horizons-may-shrink-after-clinical-trial-setback/